J&J's TECVAYLI-TALVEY Phase 3 cuts myeloma progression risk as early as second line

Johnson & Johnson's ASH 2026 press release reports Phase 3 data for its TECVAYLI (teclistamab) and TALVEY (talquetamab) combination showing reduced risk of disease progression in relapsed or refractory multiple myeloma as early as second line ^[1]. The same release carries first results for ramantamig, an investigational trispecific antibody built on DARZALEX ^[1]. Both are claims from a company headline without a trial name or hazard ratio attached.

What changed is the setting. TECVAYLI is already FDA-approved in combination with daratumumab and hyaluronidase for patients with at least one prior line of therapy, and as monotherapy after at least four prior lines ^[4]. That combination approval already reaches second-line patients, so the value of a Phase 3 readout, if it holds up when the full data appear, is randomized evidence underpinning earlier use rather than a brand-new indication. For an operator, the question is not whether J&J can treat second-line patients, it is how strong the progression-risk reduction is against the alternatives they would otherwise reach for.

Why it matters

The relapsed/refractory myeloma field already carries several BCMA-directed options with labels at the same or deeper lines. Belantamab mafodotin (Blenrep) is approved with bortezomib and dexamethasone after at least two prior lines ^[6]. The CAR-T therapies idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) sit at two-or-more and one-or-more prior lines respectively ^[7][8]. An off-the-shelf bispecific doublet that generates randomized second-line data competes directly with the logistics of autologous CAR-T and with a drug-conjugate triplet on the same shelf. That pressure lands before any of these programs have seen the TECVAYLI-TALVEY numbers.

Ramantamig raises a second front. The release describes it only as a trispecific antibody built on DARZALEX, with first results at the meeting ^[1]. The DARZALEX franchise keeps growing: net sales reached $12.41 billion over the first nine months of 2026, up 19% year over year ^[3]. Building a new multispecific on that backbone signals J&J intends to defend and extend the daratumumab platform rather than let bispecifics cannibalize it. Genmab, which originated daratumumab and reports those sales, is exposed to how that transition is managed.

The timing was not a surprise to investors. J&J's Q3 2026 earnings release, filed 13 October 2026, already flagged reporting positive Phase 3 results in multiple myeloma and listed TECVAYLI among the oncology products driving Innovative Medicine segment growth of 7.9% operationally ^[2]. The ASH slot converts that investor note into clinical detail.

What to watch

The full ASH presentation should carry the trial identity, hazard ratio and safety profile the release omits. Safety bears watching, a peer-reviewed review in Cancers (October 2026) flags frequent infections with the teclistamab-daratumumab regimen, though Prognyx could not read the full analysis and treats it as a single review ^[9].

The now-what

Teams running BCMA or CD38 assets in relapsed myeloma should reprice their second-line positioning assumptions now, before the ASH numbers land, and model an off-the-shelf doublet as the comparator rather than a CAR-T. BD teams eyeing the daratumumab-adjacent space should read ramantamig as J&J claiming trispecific white space early. Everyone else should wait for the hazard ratio before acting on a company headline.

Verdict: a moderate and rising threat to BCMA and CD38 relapsed-myeloma programs, with the real window to act opening when the full ASH 2026 data, trial name and hazard ratio become public.

What Prognyx could not verify

The release provides no trial name or NCT number, no hazard ratio and no statistical detail for the Phase 3 TECVAYLI-TALVEY claim. It gives no NCT number, mechanism, dose or trial design for ramantamig. No independent press or analyst coverage of these specific ASH 2026 results was in the provided source set.